Gansu Longshenrongfa Pharmaceutical IndustryLTD Past Earnings Performance
Past criteria checks 2/6
Gansu Longshenrongfa Pharmaceutical IndustryLTD has been growing earnings at an average annual rate of 54.6%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 39.2% per year. Gansu Longshenrongfa Pharmaceutical IndustryLTD's return on equity is 9.5%, and it has net margins of 3.7%.
Key information
54.6%
Earnings growth rate
54.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 39.2% |
| Return on equity | 9.5% |
| Net Margin | 3.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Gansu Longshenrongfa Pharmaceutical IndustryLTD makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,074 | 40 | 606 | 25 |
| 30 Jun 24 | 1,039 | 51 | 584 | 26 |
| 31 Mar 24 | 1,039 | 64 | 563 | 28 |
| 31 Dec 23 | 1,080 | 62 | 569 | 30 |
| 30 Sep 23 | 1,211 | 70 | 637 | 32 |
| 30 Jun 23 | 1,115 | 63 | 568 | 33 |
| 31 Mar 23 | 979 | 56 | 463 | 28 |
| 01 Jan 23 | 800 | 39 | 370 | 27 |
| 30 Sep 22 | 522 | 15 | 211 | 19 |
| 30 Jun 22 | 457 | -1 | 186 | 13 |
| 31 Mar 22 | 356 | -6 | 138 | 10 |
| 01 Jan 22 | 288 | -9 | 91 | 7 |
| 30 Sep 21 | 254 | 6 | 81 | 6 |
| 30 Jun 21 | 267 | 13 | 77 | 6 |
| 31 Mar 21 | 256 | 2 | 77 | 6 |
| 31 Dec 20 | 255 | 2 | 76 | 6 |
| 30 Sep 20 | 245 | -5 | 71 | 8 |
| 30 Jun 20 | 224 | -6 | 70 | 8 |
| 31 Mar 20 | 229 | 6 | 64 | 8 |
| 31 Dec 19 | 239 | 13 | 68 | 7 |
| 30 Sep 19 | 212 | 7 | 71 | 7 |
| 30 Jun 19 | 203 | 10 | 69 | 7 |
| 31 Mar 19 | 203 | 13 | 68 | 7 |
| 31 Dec 18 | 203 | 12 | 67 | 7 |
| 30 Sep 18 | 230 | 15 | 65 | 5 |
| 30 Jun 18 | 250 | 14 | 65 | 8 |
| 31 Mar 18 | 270 | 16 | 68 | 7 |
| 31 Dec 17 | 270 | 17 | 65 | 6 |
| 30 Sep 17 | 274 | 23 | 65 | 4 |
| 30 Jun 17 | 277 | 37 | 57 | 0 |
| 31 Mar 17 | 281 | 45 | 51 | 0 |
| 31 Dec 16 | 270 | 47 | 46 | 0 |
| 30 Sep 16 | 278 | 55 | 40 | 0 |
| 31 Dec 15 | 277 | 61 | 34 | 0 |
| 31 Dec 14 | 302 | 60 | 32 | 0 |
| 31 Dec 13 | 275 | 41 | 27 | 0 |
Quality Earnings: 300534 has high quality earnings.
Growing Profit Margin: 300534's current net profit margins (3.7%) are lower than last year (5.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300534's earnings have grown significantly by 54.6% per year over the past 5 years.
Accelerating Growth: 300534's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 300534 had negative earnings growth (-43.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).
Return on Equity
High ROE: 300534's Return on Equity (9.5%) is considered low.